Trial Profile

A first-in-human, open-label, non-randomized, dose-finding phase 1A study of UniCAR-T-PSMA in advanced relapsed/refractory, PSMA-positive solid tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVC 102 (Primary)
Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man

03 Dec 2020 According to a GEMoaB media release, this study is supported by a grant from the European Regional Development Fund (ERDF) provided through Saxony's Development Bank (SAB).
03 Dec 2020 According to a GEMoaB media release,this study will take place at selected Phase I and CAR-T experienced University centers in Germany.
03 Dec 2020 According to a GEMoaB media release, Prof. Dr. Ralf Bargou, Head of Comprehensive Cancer Center Mainfranken at the University Hospital Wurzburg is a coordinating investigator of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com